Multi-omic phenotyping of MAPT V337M neurons reveals early changes in axonogenesis and tau phosphorylation.

Overview

1. Institute for Neurodegenerative Diseases, University of California San Francisco,San Francisco, CA USA
2. Department of Neurology, University of California San Francisco,San Francisco, CA USA
3. Gladstone Data Science and Biotechnology Institute, The J. David Gladstone Institutes,San Francisco, CA USA
4. Quantitative Bioscience Institute, University of California San Francisco,San Francisco, CA USA
5. Department of Cellular and Molecular Pharmacology, University of California San Francisco,San Francisco, CA USA
6. Bakar Computational Health Sciences Institute, University of California San Francisco,San Francisco, CA USA
7. Department of Biochemistry and Biophysics, University of California San Francisco,San Francisco, CA USA

Abstract

Tau aggregation is a hallmark of several neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. There are disease-causing variants of the tau-encoding gene, MAPT, and the presence of tau aggregates is highly correlated with disease progression. However, the molecular mechanisms linking pathological tau to neuronal dysfunction are not well understood. This is in part due to an incomplete understanding of the normal functions of tau in development and aging, and how the associated molecular and cellular processes change in the context of causal disease variants of tau. To address these questions in an unbiased manner, we conducted multi-omic characterization of iPSC-derived neurons harboring the MAPT V337M mutation or MAPT knockdown. RNA-seq, ATAC-seq, and phosphoproteomics revealed that both the V337M mutation and tau knockdown perturbed levels of transcripts and phosphorylation of proteins related to axonogenesis or axon morphology. When we directly measured axonogenesis, we found that both MAPT V337M and MAPT knockdown caused decreased axon length. Surprisingly, we found that neurons with V337M tau had much lower tau phosphorylation than neurons with WT tau. CRISPR-based screens uncovered regulators of tau phosphorylation in neurons and found that factors involved in axonogenesis modified tau phosphorylation in both MAPT WT and MAPT V337M neurons. Intriguingly, the p38 MAPK pathway specifically modified tau phosphorylation in MAPT V337M neurons. We propose that V337M tau perturbs tau phosphorylation and axon morphology pathways that are relevant to the normal function of tau in development, which could contribute to previously reported cognitive changes in preclinical MAPT variant carriers.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

No file of the authors' code could be read here: it is described below, and read at its source.

Tracing map

Proposed by the machine: these links were found in the paper and verified at the source, without human review. The map will receive a Zenodo DOI once one of the paper's authors has validated it with their ORCID.

What the map holds:

• 1 repository of the authors' code, each at its verified commit, with its license and how the link was found in the paper;
• 0 scripts, each with its path and the digest of its content;
• no match between paragraphs and code yet;
• neither the text of the paper nor the code itself.

Its JSON (tracing-map.json) is deposited on Zenodo with its DOI once the map is validated.

Data

No dataset and no data link were found in the paper.

Data availability

Data is provided within the manuscript or supplementary information files

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 30 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 14 authors, 4 keywords, 6 funders, 90 references.

Cite

This paper

Mohl, G. A., Dixon, G., Marzette, E., McKetney, J., Samelson, A. J., Serras, C. P., Jin, J., Ariqat, N., Keys, A., Chavira, C., Li, A., Boggess, S. C., Swaney, D. L., & Kampmann, M. (2026). Multi-omic phenotyping of MAPT V337M neurons reveals early changes in axonogenesis and tau phosphorylation. NPJ dementia, 2(1), 24. https://doi.org/10.1038/s44400-026-00076-w

The tracing map gets a citation of its own once an author has validated it and it has a DOI.

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1007/s00401-026-03018-1

Tau oligomerization induces nuclear lamina invagination and chromatin remodeling in Alzheimer's disease.

Journal: Acta neuropathologica

In common: Alzheimer's / dementia, cellular / molecular, 6 references

[2] doi:10.1038/s41467-026-75882-0 [code]

A massively parallel CRISPR-based screening platform for modifiers of neuronal depolarization.

Journal: Nature communications

In common: cellular / molecular, 5 references

[3] doi:10.1038/s41467-025-62798-4 [code]

Distinct manifestations of excitatory-inhibitory imbalance associated with amyloid-β and tau in patients with Alzheimer’s disease

Journal: n/a

In common: Alzheimer's / dementia, 4 references

[4] doi:10.1080/19491034.2026.2697135

Elevation of the mechanically-sensitive e protein emerin links nuclear mechanotransduction to tau-induced cytoskeletal remodeling in neurons.

Journal: Nucleus (Austin, Tex.)

In common: Alzheimer's / dementia, cellular / molecular, 4 references

[5] doi:10.1038/s44400-026-00125-4 [code]

Regulators of interferon-responsive microglia uncovered by Genome-wide CRISPRi screening.

Journal: NPJ dementia

In common: Alzheimer's / dementia, genetics / omics, cellular / molecular, 3 references

[6] doi:10.1002/ana.78300

Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System.

Journal: Annals of neurology

In common: Alzheimer's / dementia, 3 references

[7] doi:10.1126/sciadv.aec2042 [code]

IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity.

Journal: Science advances

In common: cellular / molecular, 3 references

[8] doi:10.7554/elife.110011 [code]

Tau hyperphosphorylation impairs cooperative binding to microtubules and perturbs organelle trafficking in neurons.

Journal: eLife

In common: cellular / molecular, 3 references

[9] doi:10.1038/s41467-026-73802-w

Karyoptosis mediates cell death and neurodegeneration upon proteotoxic stress.

Journal: Nature communications

In common: Alzheimer's / dementia, cellular / molecular, 3 references

[10] doi:10.1186/s13195-026-02107-3

FKBP51 inhibition by SAFit2 modulates tau pathology and cognitive deficits in PS19 mice.

Journal: Alzheimer's research & therapy

In common: Alzheimer's / dementia, genetics / omics, cellular / molecular, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.